Phase 2 NSCLC Stage IV Clinical Trials
16 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–16 of 16 trials
Recruiting
Phase 2
A Phase II Study of Sacituzumab Tirumotecan in Combination With Furmonertinib in Patients With Non-squamous Non-Small Cell Lung Cancer Who Have Progressed After EGFR-TKI and Platinum-Based Chemotherapy
NSCLC Stage IVEGFR Gene Mutation
Tianjin Medical University Cancer Institute and Hospital25 enrolled1 locationNCT07548060
Recruiting
Phase 2
Phase II Efficacy Study of Repotrectinib in Frail and/or Elderly Patients With ROS1-rearranged Advanced NSCLC
NSCLC Stage IV
Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer30 enrolled20 locationsNCT06552234
Recruiting
Phase 2
Immunotherapy Consolidation After Radical Treatment of Synchronous Oligo-metastatic NSCLC
NSCLC Stage IV
European Organisation for Research and Treatment of Cancer - EORTC136 enrolled16 locationsNCT06219317
Recruiting
Phase 1Phase 2
Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC
NSCLC Stage IVNSCLC, Recurrent
University of Kansas Medical Center25 enrolled2 locationsNCT04467723
Recruiting
Phase 1Phase 2
Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC
NSCLC Stage IVALK Fusion Protein Expression
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins12 enrolled1 locationNCT05950139
Recruiting
Phase 2
Pemetrexed and Carboplatin With or Without Anlotinib Hydrochloride for Osimertinib-resistant Non-squamous NSCLC
NSCLC Stage IV
Fudan University105 enrolled1 locationNCT04136535
Recruiting
Phase 1Phase 2
A Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLC
NSCLC Stage IVMalignant Pleural Effusions
Wuhan YZY Biopharma Co., Ltd.96 enrolled1 locationNCT05543330
Recruiting
Phase 2
A Study on Exploring the Abscopal Effect Induced by Different Radioimmunotherapy Combination Patterns in the Treatment of Non-Small Cell Lung Cancer With Multiple Metastases
NSCLC Stage IV Without EGFR/ALK Mutation
Xinqiao Hospital of Chongqing427 enrolled1 locationNCT06947694
Recruiting
Phase 2
Study on the Optimal Combination Pattern of the Combined Treatment of Radiotherapy and Immunotherapy for the Abscopal Effect in Non-Small Cell Lung Cancer (NSCLC) With Multiple Metastases
NSCLC Stage IV Without EGFR/ALK Mutation
Xinqiao Hospital of Chongqing366 enrolled1 locationNCT06953843
Recruiting
Phase 2
Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases
Brain Metastases, AdultNSCLC Stage IV
Maastricht University Medical Center25 enrolled3 locationsNCT06401824
Recruiting
Phase 2
SBRT for Oligo-residual NSCLC After Treatment With PD-1/PD-L1 Immune Checkpoint Inhibitors
NSCLC Stage IV
Fudan University59 enrolled1 locationNCT04767009
Recruiting
Phase 2
Additional Chemotherapy for EGFRm Patients with the Continued Presence of Plasma CtDNA EGFRm At Week 3 After Start of Osimertinib 1st-line Treatment (PACE-LUNG)
NSCLC Stage IVNSCLC Stage IIIB
Goethe University50 enrolled16 locationsNCT05281406
Recruiting
Phase 2
Cranial Radiotherapy Plus Chemoimmunotherapy in Untreated Driver-mutation Negative NSCLC With Active Brain Metastasis
NSCLC Stage IV
Fudan University40 enrolled1 locationNCT06501378
Recruiting
Phase 2
Cranial Radiotherapy Plus Chemoimmunotherapy in Untreated Driver-mutation Negative NSCLC With Stable Brain Metastasis
Brain MetastasesNSCLC Stage IV
Fudan University54 enrolled1 locationNCT06501391
Recruiting
Phase 2
Treatment Response Adapted Hybrid Radiotherapy in Metastatic Non-small Cell Lung Cancer Receiving First-line Immunotherapy
NSCLC Stage IV
Fudan University146 enrolled1 locationNCT06313541
Recruiting
Phase 2
Efficacy and Safety of Anti-PD-1/PD-L1 Treatment +/- UV1 Vaccination in Patients With Non-small Cell Lung Cancer
OncologyNSCLC Stage IV
Vestre Viken Hospital Trust138 enrolled1 locationNCT05344209